Grants per year
Personal profile
Research Interests
Dr. Beauchamp's research has focused on developing drugs for non-traditional targets through inhibiting protein-protein interactions in order to affect cellular function and target cancer cells. Current work is investigating novel interactors with mTORC components in order to developing novel therapeutic strategies that target the mTOR pathways in myeloid leukemias.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, Tumor Biology, Georgetown University
… → 2010
Research interests keywords
- Biochemistry: Proteins
- Blood Cancer (leukemia and lymphomas)
- Cancer Biology
- Drug Discovery
- Signal Transduction
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
Targeting Novel Protein Complexes for the Treatment of Acute Myeloid Leukemia
Platanias, L. C., Platanias, L. C., Beauchamp, E. M., Beauchamp, E. M., Eklund, E. A., Eklund, E. A., Altman, J. K. & Altman, J. K.
6/1/19 → 5/31/24
Project: Research project
-
VA IPA for Elspeth Beauchamp
Platanias, L. C. & Beauchamp, E. M.
10/1/15 → 7/31/19
Project: Research project
-
-
Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms
Saleiro, D., Wen, J. Q., Kosciuczuk, E. M., Eckerdt, F., Beauchamp, E. M., Oku, C. V., Blyth, G. T., Fischietti, M., Ilut, L., Colamonici, M., Palivos, W., Atsaves, P. A., Tan, D., Kocherginsky, M., Weinberg, R. S., Fish, E. N., Crispino, J. D., Hoffman, R. & Platanias, L. C., Dec 2022, In: Nature communications. 13, 1, 1750.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Inhibitory effects of Tomivosertib in acute myeloid leukemia
Suarez, M., Blyth, G. T., Mina, A. A., Kosciuczuk, E. M., Dolniak, B., Dinner, S., Altman, J. K., Eklund, E. A., Saleiro, D., Beauchamp, E. M. & Platanias, L. C., May 11 2021, In: Oncotarget. 12, 10, p. 955-966 12 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations -
OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia
Eisfelder, B. J., Saygin, C., Wynne, J., Colton, M. W., Fischietti, M., Beauchamp, E. M., Cheng, J. X., Odenike, O., Roboz, G., Alachkar, H. & Stock, W., Mar 2021, In: Blood cancer journal. 11, 3, 48.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations -
Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma
Fischietti, M., Eckerdt, F., Blyth, G. T., Arslan, A. D., Mati, W. M., Oku, C. V., Perez, R. E., Lee-Chang, C., Kosciuczuk, E. M., Saleiro, D., Beauchamp, E. M., Lesniak, M. S., Verzella, D., Sun, L., Fish, E. N., Yang, G. Y., Qiang, W. & Platanias, L. C., May 6 2021, In: Oncogene. 40, 18, p. 3273-3286 14 p.Research output: Contribution to journal › Article › peer-review
5 Scopus citations -
Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening
Mishra, R. K., Clutter, M. R., Blyth, G. T., Kosciuczuk, E. M., Blackburn, A. Z., Beauchamp, E. M., Schiltz, G. E. & Platanias, L. C., Oct 1 2019, In: Chemical Biology and Drug Design. 94, 4, p. 1813-1823 11 p.Research output: Contribution to journal › Article › peer-review
7 Scopus citations